TXNDC5 and prostate carcinoma: Duivenvoorden et al. found that when TXNDC5 was stably knocked down using shRNA or overexpressed in prostate carcinoma 22Rv1 cells, tumor growth and proliferation in vitro and in BALB/c nude mice were inhibited and accelerated, respectively [47,48].